𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biochemical Modulation of 5-Fluorouracil with Murine Interferon-α/β Against Murine Renal Cell Carcinoma

✍ Scribed by Ken Marumo; Mototsugu Oya; Masaru Murai

Book ID
108976238
Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
576 KB
Volume
4
Category
Article
ISSN
0919-8172

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of 5-fluorouracil, interf
Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
✍ Julie A. Ellerhorst; Avishay Sella; Robert J. Amato; Shi-Ming Tu; Randall E. Mil 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d

A phase II trial of interferon-α and 5-f
A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

A Phase II trial of intravenous gemcitab
A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH